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Abstract: Advances in current understanding of the pathophysiology of atopic dermatitis have 
led to improved targeting of the structural deficiencies in atopic skin. Ceramide deficiency 
appears to be one of the major alterations in atopic dermatitis and the replenishment of this 
epidermal component through topically applied ceramide based emollients appears to be safe, 
well tolerated, and effective. Recently a ceramide hyaluronic acid foam has become commercially 
available and increasing evidence supports its safety and efficacy in patients who suffer from 
atopic dermatitis.
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Current understanding
Atopic dermatitis (AD) is one of the most common dermatologic disorders known, 
occurring in up to 20 percent of Caucasian school children.1,2 Due to this high prevalence 
in the pediatric population, a tremendous amount of effort has been expended to 
elucidate the pathophysiology and etiology of this skin condition. Current understanding 
of this cutaneous disorder including the genetics, immunology, response to microbes, 
and the breakdown of the skin as a barrier have facilitated the development of products 
that remedy the deficits now recognized in the outermost layers of the skin. The 
breakdown of the skin barrier recognized in AD is due to impairment of the stratum 
corneum resulting from a diminution in lipids, chiefly ceramides.3 The stratum corneum 
lipids serve to retain water as well as providing a permeability barrier. This barrier is 
made up of several components including the corneocytes and their surrounding mature 
lamellar bodies filled with ceramides, cholesterol, and fatty acids. These hydrophobic 
molecules provide the skin with a means to circumvent the loss of moisture which 
would result in the breakdown of the epidermal protective layer, superinfection by 
opportunistic organisms, and an increase in antigen exposure. Current treatment norms 
consist of both restoration of the barrier using traditional emollients and altering 
the immune hyper-responsiveness with topical steroids or immunomodulators.4 
Traditional emollients or moisturizers include ointments, emulsions, and creams that 
work by reducing transepidermal water loss either through occlusion or the attraction 
of moisture through humectants. These alone or in combination have proven to be 
safe and effective when used correctly. Most patients with mild to moderate AD will 
respond to a regimen of enhanced lubrication, especially if pruritus and bacterial 
colonization are also managed effectively.5 The well-known potential side effects of 
topical steroids including systemic absorption, thinning of the skin, telangiectasia, 
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striae, rosacea, and acne,6 while infrequently encountered, are 
often unacceptable to patients and parents. Further certain 
traditional emollients in lotion or ointment bases are often in 
formulations that patients will rarely use consistently.
Common emollient ingredients  
in HylatopicPlus®
Dimethicone is a polymer of silicone and oxygen that works 
as an effective occlusive. Dimethicone’s popularity and 
widespread use is likely attributable to its property of “oil 
free” occlusion and the ascribed safety and tolerability of 
this component.7 Furthermore in addition to the dimethicone 
added as an occlusive, HylatopicPlus® (Onset Dermatologics, 
Cumberland, RI) also includes petrolatum.
Glycerin is a simple organic compound that functions 
as a humectant. Like all humectants, without appropriate 
occlusion this can actually increase transepidermal water 
loss by attracting additional moisture from the dermis into 
the epidermis with ultimate loss of cutaneous moisture into 
the ambient air.8
Propylene glycol is a simple organic compound that 
also functions as a humectant. Historically this ingredient 
was believed to be a common cause of contact dermatitis. 
More recently, this has been recognized not to be the case 
in most available dermatologic products. In concentrations 
above 5% propylene glycol may cause an irritant contact 
dermatitis although this immune-mediated response is 
unlikely at the lower concentrations used in most newer 
emollients such as HylatopicPlus. Furthermore, true allergic 
contact dermatitis from propylene glycol is rare for most 
available over-the-counter emollients.9
Compliance based on properties  
of various prior emollient studies
Patient compliance in chronic dermatologic conditions 
is quite poor. Recognition of this phenomenon has led 
to speculation that improvement in vehicle properties 
which would cater to patient preferences could potentially 
improve therapeutic adherence. Noncompliance rates may 
be as high as 40% in chronic dermatologic conditions.10 
Patients appear to prefer topical foams and solutions to 
ointments and oils regardless of ethnic background or site 
of application. This preference for foams and solutions 
also appears to improve compliance11 and suggests that a 
focus on vehicles that cater to patient preferences would 
improve compliance and ultimately their underlying 
  cutaneous condition.
Function of emollients in the 
epidermal barrier: how do 
these agents repair the skin 
biochemically?
Emollients work in the treatment of AD by improving the 
barrier function of the skin. The “outside in” theory of 
AD contends that certain genetic abnormalities lead to a 
defective skin barrier that allows allergens and pathogens 
to penetrate. The resultant increased water loss and an 
allergic inflammatory response with release of cytokines 
can exacerbate skin damage. Patients who have mutations 
in the gene that encodes for filaggrin have a threefold 
increased risk of AD.12 Filaggrin, an interfilamentous 
protein that aggregate keratin into tight bundles, induces the 
corneocyte to become flattened.13 Individuals who have the 
filaggrin mutations have different ratios of ceramide types 
and generally lower quantities of certain ceramides than 
nonatopic patients.14 While traditional emollients improve 
xerosis and may reduce antigen exposure, ceramide-dominant 
emollients appear to improve barrier function and break the 
cycle of antigen exposure, inflammation, and water loss. 
Transepidermal water loss and desquamation are increased 
in AD. Consistent use of emollients reduces the level of both 
of these phenomena. However, use of traditional emollients 
does not have any effect on inflammatory cytokine levels 
or ceramide levels.15 These traditional non-ceramide-based 
emollients alleviate symptoms but do not address the 
fundamental element of the problem, that is, a ceramide 
deficiency. Application of ceramide-containing emollients 
changes the structure of the stratum corneum to replenish and 
restore the number and structure of extracellular lipid bilayer 
components as compared to untreated atopic skin.16 Objective 
measurements, like the severity scoring of AD, SCORAD,17 
and transepidermal water loss have both demonstrated greater 
improvement after application of ceramide emollients over 
traditional emollients.18
Topical calcineurin inhibitors have become an alternative 
to topical steroids in the treatment of AD. These have a 
relatively benign side effect profile and can be used on the 
face and intertriginous areas. Calcineurin inhibitors work by 
blocking T-cell activation and replication, ultimately dulling 
TNF alpha levels. When comparing 1% pimecrolimus cream 
to foam ceramide-containing emollients in an investigator 
blinded head-to-head comparison trial, both products resulted 
in a substantial improvement in patient symptoms and the 
investigator’s global assessment. There was no statistically 
significant difference in the efficacy of topical ceramide foam 
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when compared to pimecrolimus cream.6 The basis for the 
action of the hyaluronic-containing emollient is the delivery 
of the moisturizer through the stratum corneum and into the 
dermis, thereby theoretically depositing ceramide proteins in 
the most anatomically valuable location.19 Hyaluronic acid 
also interacts with CD44 on the surface of keratinocytes, 
stimulating lamellar body formation and secretion.20
What evidence is there of the safety 
of ceramide emollients?
Compared to the even small risks of topical steroids or 
immunomodulators, topical ceramides appear to be quite 
safe. Topical steroids may potentially cause cutaneous 
atrophy, striae, telangiectasias, and acne. Systemic absorption 
is always a potential concern. Topical calcineurin inhibitors 
like pimecrolimus (Elidel®, Novartis, Basel, Switzerland) 
cream or tacrolimus (Protopic®, Astellas Pharma Inc, Tokyo, 
Japan) ointment have received black box warnings as a class 
of topical immunomodulators based on the theoretical risk of 
increasing malignancy.21 This black box warning is the only 
one ever given by the FDA based on a theoretical risk that 
currently appears to be poorly substantiated. These warnings 
have not led to commensurate label changes outside the 
United States.22–25 Topical application of these calcineurin 
inhibitors generally appears to be safe. There is no need for 
laboratory monitoring when topical calcineurin inhibitors 
are prescribed, as compared to systemic treatment of AD 
with methotrexate or cyclosporine which potentially can 
lead to serious side effect profiles including teratogenicity 
and leukopenia. By comparison, review of the profile of 
ceramide-containing emollients recently has shown these 
agents to be extremely safe.26
Nine ceramides are present in the stratum corneum.6 
These important compounds comprise half of the lipids in 
the stratum corneum which help to mediate the permeability 
of the stratum corneum barrier. As these polar lipids are 
  present in large quantities in normal skin, many current 
topical   regimens also contain ceramides in large quantities.
Ceramides are available in two ways: via synthetic 
  synthesis (which normally provides an economical and pure 
source of ceramides); or from natural sources which, while 
more biologically similar to those found in human skin, are 
often more expensive. The natural-source ceramides have a risk 
of contamination and may be viewed as potential sources of 
infection. Natural sources of ceramides include bovine central 
nervous systems, raising concern about   contamination with 
prions that can transmit bovine spongiform encephalopathy 
or “mad cow disease.”27 Further, ceramide can be involved 
in cellular signaling and, in sufficient quantities, can be toxic 
to cells by migrating across the cell membrane and inducing 
apoptosis or inhibiting growth.28 Cell-permeant ceramide 
inhibits keratinocyte proliferation and increases cytotoxicity 
by disrupting the mitochondrial membrane action potential. 
Thus, natural ceramides, while intuitively the better option, are 
not perfect agents for topical emollients. Synthetic ceramides 
can be pure, cheaper to produce, and have characteristics that 
produce effects that are desirable without the unwanted poten-
tial biologic effects, because these lipids do not penetrate the 
cell membrane.29 Synthetic ceramides even at 100% presumed 
absorption after application have not been found to produce 
any ill effects either on skin, test animal eyes, or with oral 
administration.26
What evidence is there  
of acceptability to patients?
Previously, patients requiring long-term use of topical 
corticosteroid had no alternative therapies readily available 
to them. Now, however, topical calcineurin inhibitors offer 
a nonsteroidal alternative with the advantage of avoiding 
common topical steroid-induced side effects. The calcineurin 
inhibitors may be difficult to prescribe for particularly 
anxious patients who have been scared by their “internet 
research,” piquing their concern for potential increased 
malignancy or who simply want the “safest” alternative. 
Furthermore calcineurin inhibitors are FDA approved for 
the treatment of children 2 years of age and older. Topical 
ceramide emollient foams offer cutaneous barrier improve-
ment, are remarkably safe, and are approved for use even 
in young children.
Costs and conclusion
As cost may impact compliance and indirectly, efficacy, 
newer prescription devices like Hylatopic, which are 
expensive, must be evaluated with respect to cost versus 
benefit. The use of traditional emollients and topical steroids 
is effective in the majority of patients suffering from AD 
and these agents can be employed safely and inexpensively. 
The addition of topical calcineurin inhibitors is a safe and 
effective therapy or these agents may serve as augmentation 
to treatment. Further understanding of the pathophysiology 
of AD has resulted in new, effective, and safe treatment in 
those patients who have failed other regimens or refuse to 
use those modalities to effectively control the underlying 
skin disease.
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